re: Proposed settlement of infringement litigation with Teva Pharmaceuticals involving sharing of the exclusivity period for the drug Paraplatin.
Main Menu
- About the FTC
- What We Do
- Our History
- Commissioners
- Bureaus & Offices
- Bureau of Competition
- Bureau of Consumer Protection
- Bureau of Economics
- Office of Congressional Relations
- Office of Equal Employment and Workplace Inclusion
- Office of International Affairs
- Office of the Executive Director
- Office of the General Counsel
- Office of Policy Planning
- Regional Offices
- Office of Administrative Law Judges
- Office of Public Affairs
- Office of the Secretary
- Biographies
- Budgets
- Performance
- Office of Inspector General
- FTC Imposter Scams
- What You Need to Know About the Office of the Inspector General
- The Inspector General
- Commemorating the 40th Anniversary of the IG Act
- Council of the Inspector General on Integrity and Efficiency (CIGIE)
- Oversight.gov
- Reporting Fraud, Waste, Abuse or Mismanagement
- Whistleblower Protection
- OIG Audits and Evaluations
- OIG Investigations
- OIG Reading Room
- Notice Concerning Nondisclosure Policies, Forms, or Agreements
- Contact the OIG
- FOIA
- Careers at the FTC
- News & Events
- Enforcement
- Policy
- Tips & Advice
- I Would Like To...
